Discover
etrolizumab (RG7413) / RocheEtrolizumab: Regulatory submissions in US/EU for Crohn's disease in 2022 (Roche) - Apr 22, 2020 - Q1 2020 Results
mirikizumab (LY3074828) / Eli LillyMirikizumab: Primary completion of P3 LUCENT 2 trial (NCT03524092) in moderate-to-severe ulcerative colitis in Jun 2021 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 LUCENT 2 trial in moderate-to-severe ulcerative colitis in Jun 2023; Primary completion and completion of P3 LUCENT 3 trial (NCT03519945) in moderate-to-severe ulcerative colitis in Aug 2023
Alofisel (darvadstrocel) / TakedaADMIRE-CD-II: Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) (clinicaltrials.gov) - Apr 21, 2020 - P3; N=554; Active, not recruiting; Sponsor: Tigenix S.A.U.; Recruiting --> Active, not recruiting
mirikizumab (LY3074828) / Eli LillyMirikizumab: Primary completion of P3 LUCENT 1 trial (NCT03518086) in moderate-to-severe ulcerative colitis in Sep 2020 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 LUCENT 1 trial in moderate-to-severe ulcerative colitis in Dec 2021
mirikizumab (LY3074828) / Eli LillyMirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn’s disease in Feb 2022 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 VIVID-1 trial for Crohn’s disease in Jul 2023; Primary completion and completion of P3 VIVID-2 trial (NCT04232553) for Crohn’s disease Nov 2023
Entyvio (vedolizumab) / TakedaVedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease (clinicaltrials.gov) - Apr 24, 2020 - P3; N=215; Active, not recruiting; Sponsor: Takeda; Trial primary completion date: Apr 2020 --> Sep 2020
Stelara (ustekinumab) / J&JStelara: Patent expiry in US in 2023 (J&J) - Apr 26, 2020 - Annual Meeting of Shareholders
Cimzia (certolizumab pegol) / Astellas, UCB, Eli LillyCHERISH: A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (clinicaltrials.gov) - Apr 21, 2020 - P1b; N=20; Suspended; Sponsor: UCB Biopharma S.P.R.L.; Recruiting --> Suspended
Rinvoq (upadacitinib) / AbbVieRinvoq: Newly added patent in Orange Book (Orange Book) - Apr 22, 2020 - Expiry on October 17, 2036
TD-1473 / J&JTheravance Biopharma announces peer-reviewed publication highlighting TD-1473 program in the Journal of Crohn’s and Colitis (PRNewswire) - Apr 20, 2020 - "Theravance Biopharma...announced the publication of a peer-reviewed paper summarizing positive results from completed Phase 1 clinical and preclinical studies of TD-1473, the Company's gut-selective pan-Janus kinase (JAK) inhibitor. The manuscript...highlights a broad collection of data demonstrating minimal systemic drug exposure, local target engagement, and trends toward reduced markers of ulcerative colitis disease activity following TD-1473 administration versus placebo."
